Table 32Study information table for trials comparing antidepressants with placebo

Escitalopram versus placeboSertraline versus placeboParoxetine versus placeboCitalopram versus placeboDuloxetine versus placeboVenlafaxine versus placeboImipramine versus placebo
No. of trials
(total participants)
6 RCTs
(2136)
2 RCTs
(706)
8 RCTs
(2784)
1 RCT
(34)
4 RCTs
(1491)
12 RCTs
(3470)
1 RCT
(28)
Study ID
LENZE2005
MCLEOD1992
N/% female (see Appendix 15d for data for individual studies)2136/range
53–67%
706/range
55–58%
2784/range
55–70%
34/62%1491/range
62–68%
3470/range
39%–68%
28/not reported
Mean age (years) (see Appendix 15d for data for individual studies)45414169434241
Diagnosis(1) GAD by DSM-IV
(2) GAD by DSM-IV-TR
(3)–(6) GAD by DSM-IV
(1)–(2) GAD by DSM-IV(1) GAD by DSM-IV
(2) GAD by DSM-IV-TR
(3)–(8) GAD by DSM-IV
GAD by DSM-IV(1)–(4) GAD by DSM-IV(1)–(10) GAD by DSM-IV
(11) GAD by DSM-III-R
(12) GAD by DSM-IV
GAD by DSM- III-R
Baseline severity (HAM-A): mean (SD)
  1. Not reported
  2. Escitalopram 27.06 (4.46); placebo 27.1 (4.6)
  3. Escitalopram 24.2 (SE = 0.4); placebo 23.7 (SE = 0.3)
  4. Escitalopram 23.40 (4.40); placebo 23.2 (4.2)
  5. Escitalopram 23.0 (0.2); placebo 22.7 (0.2)
  6. Escitalopram 23.00 (2.30); placebo 23.1 (4.9)
  1. Sertraline 24.6 (4.6); placebo 25.0 (4.9)
  2. Sertraline 24.5 (3.1); placebo 24.1 (2.8)
  1. Not reported
  2. Paroxetine 27.06 (4.46); placebo 27.1 (4.6)
  3. Paroxetine 24.5 (3.71); placebo 24.83 (3.64)
  4. Not reported
  5. Paroxetine 26.0 (0.4); placebo 25.9 (0.4)
  6. Paroxetine 24.2 (0.30); placebo 24.1 (0.30)
  7. Paroxetine 23.5 (3.3); placebo 24.0 (4.9)
  8. Paroxetine 24.1 (3.6); placebo 24.4 (3.7)
Citalopram 24.1 (4.6); placebo 23.1 (3.8)
  1. Duloxetine 25.6 (5.8); placebo 25.0 (5.8)
  2. Duloxetine 25.5 (7.3); placebo 25.8 (7.6)
  3. Duloxetine 27.5 (7.3); placebo 27.3 (7.3)
  4. Duloxetine 22.6 (7.4); placebo 23.5 (7.9)
  1. Venlafaxine 26.6 (range 20–44); placebo 26.7 (range 20–52)
  2. Venlafaxine 23.8 (SE = 0.3); placebo 23.7 (SE = 0.3)
  3. Venlafaxine 23.4 (4.1); placebo 23.7 (4.2)
  4. Venlafaxine 25.0 (5.0); placebo 25.0 (5.0)
  5. Venlafaxine 27.8 (not reported); placebo 27.6 (not reported)
  6. Venlafaxine 25 (5.4); placebo 25.0 (5.8)
  7. Venlafaxine 27.4 (SE = 0.4); placebo 26.8 (SE = 0.8)
  8. Venlafaxine 28 (not reported); placebo 28 (not reported)
  9. Venlafaxine 26.8 (4.6); placebo 27.4 (5.5)
  10. Venlafaxine 27.3 (7.6); placebo 27.3 (7.3)
  11. Venlafaxine 27.8 (4.8); placebo 28.5 (6.4)
  12. Venlafaxine 24.7 (4.4); placebo 24.1 (4.2)
Imipramine 25.3 (4.0); placebo 25.1 (2.0)
Treatment lengthRange 8 to 12 weeksRange 10 to 12 weeksRange 6 to 8 weeks8 weeksRange 9 to 10 weeksRange 6 to 24 weeks6 weeks
Follow-upEnd of treatmentEnd of treatmentEnd of treatmentEnd of treatmentEnd of treatmentEnd of treatmentEnd of treatment

From: 8, PHARMACOLOGICAL AND PHYSICAL INTERVENTIONS

Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.